Canada Life’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$234M Sell
1,675,983
-8,858
-0.5% -$1.24M 0.42% 39
2025
Q4
$207M Sell
1,684,841
-570,987
-25% -$69.4M 0.36% 47
2025
Q3
$254M Buy
2,255,828
+28,270
+1% +$3.21M 0.36% 46
2025
Q2
$247M Buy
2,227,558
+31,793
+1% +$3.38M 0.39% 43
2025
Q1
$246M Buy
2,195,765
+99,101
+5% +$10.2M 0.43% 37
2024
Q4
$194M Sell
2,096,664
-72,343
-3% -$6.51M 0.33% 53
2024
Q3
$182M Buy
2,169,007
+36,966
+2% +$2.82M 0.32% 54
2024
Q2
$146M Buy
2,132,041
+323,005
+18% +$21.6M 0.28% 65
2024
Q1
$133M Buy
1,809,036
+21,224
+1% +$1.63M 0.27% 69
2023
Q4
$144M Sell
1,787,812
-29,436
-2% -$2.29M 0.32% 61
2023
Q3
$136M Buy
1,817,248
+6,694
+0.4% +$515K 0.33% 58
2023
Q2
$140M Buy
1,810,554
+191,686
+12% +$15.3M 0.33% 57
2023
Q1
$135M Buy
1,618,868
+45,794
+3% +$3.79M 0.33% 58
2022
Q4
$136M Sell
1,573,074
-401,689
-20% -$31.8M 0.36% 54
2022
Q3
$122M Sell
1,974,763
-33,544
-2% -$2.12M 0.35% 55
2022
Q2
$124M Sell
2,008,307
-20,231
-1% -$1.25M 0.33% 61
2022
Q1
$127M Buy
2,028,538
+111,090
+6% +$7.1M 0.27% 72
2021
Q4
$139M Buy
1,917,448
+204,648
+12% +$14.1M 0.29% 65
2021
Q3
$120M Buy
1,712,800
+23,984
+1% +$1.68M 0.28% 66
2021
Q2
$116M Sell
1,688,816
-150,416
-8% -$10M 0.27% 73
2021
Q1
$118M Sell
1,839,232
-342,908
-16% -$22.1M 0.29% 69
2020
Q4
$127M Buy
2,182,140
+104,971
+5% +$6.33M 0.24% 97
2020
Q3
$131M Sell
2,077,169
-3,363
-0.2% -$233K 0.29% 88
2020
Q2
$160M Sell
2,080,532
-109,754
-5% -$8.41M 0.37% 67
2020
Q1
$165M Buy
2,190,286
+15,861
+0.7% +$1.1M 0.44% 53
2019
Q4
$140M Buy
2,174,425
+315,662
+17% +$20.6M 0.31% 76
2019
Q3
$118M Buy
1,858,763
+45,394
+3% +$2.97M 0.28% 85
2019
Q2
$122M Sell
1,813,369
-6,116
-0.3% -$402K 0.28% 82
2019
Q1
$118M Buy
1,819,485
+181,393
+11% +$12.1M 0.31% 79
2018
Q4
$99.1M Sell
1,638,092
-270,402
-14% -$18.9M 0.28% 81
2018
Q3
$148M Sell
1,908,494
-133,568
-7% -$10.1M 0.35% 65
2018
Q2
$145M Buy
2,042,062
+100,519
+5% +$7.1M 0.34% 65
2018
Q1
$147M Sell
1,941,543
-36,198
-2% -$2.88M 0.35% 64
2017
Q4
$141M Buy
1,977,741
+141,241
+8% +$10.7M 0.33% 70
2017
Q3
$148M Buy
1,836,500
+67,664
+4% +$5.17M 0.37% 65
2017
Q2
$125M Buy
1,768,836
+96,802
+6% +$6.44M 0.33% 68
2017
Q1
$113M Sell
1,672,034
-43,819
-3% -$3.08M 0.31% 68
2016
Q4
$123M Buy
1,715,853
+133,741
+8% +$9.94M 0.35% 62
2016
Q3
$125M Buy
1,582,112
+30,741
+2% +$2.5M 0.36% 60
2016
Q2
$129M Buy
1,551,371
+253,457
+20% +$22.5M 0.39% 59
2016
Q1
$119M Buy
1,297,914
+14,656
+1% +$1.32M 0.43% 55
2015
Q4
$130M Buy
1,283,258
+18,958
+1% +$1.97M 0.5% 45
2015
Q3
$124M Buy
1,264,300
+196,515
+18% +$21.8M 0.49% 44
2015
Q2
$125M Buy
1,067,785
+46,073
+5% +$5.03M 0.43% 53
2015
Q1
$100M Sell
1,021,712
-41,453
-4% -$4.21M 0.34% 71
2014
Q4
$100M Sell
1,063,165
-315,962
-23% -$32.7M 0.33% 71
2014
Q3
$147M Sell
1,379,127
-60,420
-4% -$5.92M 0.49% 43
2014
Q2
$119M Sell
1,439,547
-188,840
-12% -$14.7M 0.39% 55
2014
Q1
$115M Buy
1,628,387
+356,093
+28% +$27.9M 0.4% 54
2013
Q4
$96M Sell
1,272,294
-16,257
-1% -$1.13M 0.34% 64
2013
Q3
$80.8M Buy
1,288,551
+821,162
+176% +$49.1M 0.32% 72
2013
Q2
$23.9M Buy
+467,389
New +$24.4M 0.16% 121

Other funds holding GILD

Canada Life's GILD Position: Q1 2026 in Review

Canada Life reduced its Gilead Sciences (GILD) stake by 0.53% in Q1 2026, selling an estimated $1.24M and leaving 1,675,983 shares worth $234M. The position accounts for 0.42% of the portfolio, ranked #39.

Canada Life first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $254M in Q3 2025. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Canada Life held 1,675,983 shares of Gilead Sciences worth $234M as of Q1 2026.
  • Canada Life sold 8,858 Gilead Sciences shares in Q1 2026, an estimated $1.24M.
  • Gilead Sciences made up 0.42% of Canada Life's portfolio in Q1 2026, its #39 holding.
  • Canada Life first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Canada Life's Gilead Sciences position peaked at $254M in Q3 2025.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.